
|Videos|October 8, 2020
Rapid Readouts: Phase 3 HERO Trial
Advertisement
Supported by an unrestricted educational grant from Myovant Sciences.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas
2
Tacabrutideg Is Tolerable and Shows Efficacy Signals Across BTK Inhibitor–Naive CLL and Other B-Cell Malignancies
3
Subcutaneous Blinatumomab Yields High Efficacy Rates in R/R Ph+ B-ALL
4
Real-World Analysis Reveals Liso-Cel Elicits High Response Rates in R/R Mantle Cell Lymphoma
5








































































